A molecular pathway analysis of the glutamatergic–monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment

Journal of Neural Transmission

Volumn 122, Issue 3, 2015, Pages 465-475

  Drago, Antonio ^a   Cocchi, Enrico ^a   Crisafulli, Concetta ^b   Serretti, Alessandro ^a,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Citalopram; Glutamatergic; Major depressive disorder; Molecular pathways; Monoaminergic

Indexed keywords

AKAP12 PROTEIN, HUMAN; ANTIDEPRESSANT AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CAMK2D PROTEIN, HUMAN; CELL CYCLE PROTEIN; CITALOPRAM; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE ANCHORING PROTEIN;

ADOLESCENT; ADULT; AGED; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC ASSOCIATION STUDY; GENETICS; HUMAN; MALE; MIDDLE AGED; PHARMACOGENETICS; PSYCHOLOGICAL RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; YOUNG ADULT;

A KINASE ANCHOR PROTEINS; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL CYCLE PROTEINS; CITALOPRAM; CYCLIC AMP; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 84939883962     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1267-2     Document Type: Review

References (55)

1. Andrade L, Caraveo-anduaga JJ, Berglund P, Bijl RV, Graaf RD, Vollebergh W, Dragomirecka E, Kohn R, Keller M, Kessler RC, Kawakami N, Kiliç C, Offord D, Bedirhan Ustun T, Wittchen H-U (2003) The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res 12:3–21. doi:10.1002/mpr.138
2. Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34:1130–1144. doi:10.1093/schbul/sbn114
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354. doi:10.1016/S0006-3223(99)00230-9
4. Cheng ATA (2000) Psychosocial and psychiatric risk factors for suicide: Case–control psychological autopsy study. Br J Psychiatry 177:360–365. doi:10.1192/bjp.177.4.360
5. Choi YK, Kim K-W (2008) AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. FEBS J 275:2338–2353. doi:10.1111/j.1742-4658.2008.06387.x
6. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA (2002) cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci Off J Soc Neurosci 22:3262–3268
7. Crespo-Facorro B, Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, Martínez-García O, Pardo-García G, Vázquez-Barquero JL (2007) Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 41:659–666. doi:10.1016/j.jpsychires.2006.05.002
8. De Leon J, Armstrong SC, Cozza KL (2005) The dosing of atypical antipsychotics. Psychosomatics 46:262–273. doi:10.1176/appi.psy.46.3.262
9. Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, Neve RL, Nestler EJ, Carlezon WA Jr (2009) Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci Off J Soc Neurosci 29:1855–1859. doi:10.1523/JNEUROSCI.5104-08.2009
10. Drago A, Serretti A (2011) Sociodemographic features predict antidepressant trajectories of response in diverse antidepressant pharmacotreatment environments: a comparison between the STAR*D study and an independent trial. J Clin Psychopharmacol. doi:10.1097/JCP.0b013e3182189c64
11. Drago A, Crisafulli C, Sidoti A, Serretti A (2011) The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol 94:418–460. doi:10.1016/j.pneurobio.2011.05.009
12. Dwivedi Y, Rizavi HS, Shukla PK, Lyons J, Faludi G, Palkovits M, Sarosi A, Conley RR, Roberts RC, Tamminga CA, Pandey GN (2004) Protein kinase a in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol Psychiatry 55:234–243. doi:10.1016/j.biopsych.2003.11.003
13. Emsley R, Rabinowitz J, Medori R (2007) Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 89:129–139. doi:10.1016/j.schres.2006.09.013
14. Flockhart D (2007) Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine
15. Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP (2005) Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 20:199–205. doi:10.1097/00004850-200507000-00002
16. Goforth HW, Holsinger T (2007) Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT 23:23–25. doi:10.1097/01.yct.0000263257.44539.23
17. Gunduz-Bruce H (2005) Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry 162:1966–1969. doi:10.1176/appi.ajp.162.10.1966
18. Hirschfeld RMA, Russell JM, Delgado PL, Fawcett J, Friedman RA, Harrison WM, Koran LM, Miller IW, Thase ME, Howland RH, Connolly MA, Miceli RJ (1998) Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 59:669–675. doi:10.4088/JCP.v59n1205
19. Inestrosa NC, Arenas E (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11:77–86. doi:10.1038/nrn2755
20. Joober R, Rouleau GA, Lal S, Bloom D, Lalonde P, Labelle A, Benkelfat C (2005) Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res 77:35–41. doi:10.1016/j.schres.2005.01.008
21. Jurado S, Biou V, Malenka RC (2010) A calcineurin/AKAP complex is required for NMDA receptor-dependent long-term depression. Nat Neurosci 13:1053–1055. doi:10.1038/nn.2613
22. Kessler RC, Birnbaum HG, Shahly V, Bromet E, Hwang I, McLaughlin KA, Sampson N, Andrade LH, de Girolamo G, Demyttenaere K, Haro JM, Karam AN, Kostyuchenko S, Kovess V, Lara C, Levinson D, Matschinger H, Nakane Y, Browne MO, Ormel J, Posada-Villa J, Sagar R, Stein DJ (2010) Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. Depress Anxiety 27:351–364. doi:10.1002/da.20634
23. Kudoh A, Takahira Y, Katagai H, Takazawa T (2002) Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 95:114–118. doi:10.1097/00000539-200207000-00020
24. Kuo H-W, Liu SC, Tsou H–H, Liu S-W, Lin K-M, Lu S-C, Hsiao M-C, Hsiao C-F, Liu C-Y, Chen C-H, Lu M-L, Shen WW, Tang H-S, Liu S-I, Chang L-H, Wu H-Y, Chang Y-S, Yeh T-K, Chen AC, Liu Y-L (2013) CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics 14:1191–1201. doi:10.2217/pgs.13.105
25. Lejeune F, Gobert A, Rivet J-M, Mark JM (1994) Blockade of transmission at NMDA receptors facilitates the electrical and synthetic activity of ascending serotoninergic neurones. Brain Res 656:427–431. doi:10.1016/0006-8993(94)91490-7
26. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223. doi:10.1056/NEJMoa051688
27. McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E (2010) The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 15:237–249. doi:10.1038/mp.2009.80
28. McGrath P (2006) Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 163:1542. doi:10.1176/appi.ajp.163.9.1542
29. Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66:807–822. doi:10.1146/annurev.biochem.66.1.807
30. Morishita S, Arita S (2003) Possible predictors of response to fluvoxamine for depression. Hum Psychopharmacol 18:197–200. doi:10.1002/hup.469
31. Muñoz FJ, Godoy JA, Cerpa W, Poblete IM, Huidobro-Toro JP, Inestrosa NC (2014) Wnt-5a increases NO and modulates NMDA receptor in rat hippocampal neurons. Biochem Biophys Res Commun 444:189–194. doi:10.1016/j.bbrc.2014.01.031
32. Nibuya M, Nestler EJ, Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci Off J Soc Neurosci 16:2365–2372
33. Pallotta M, Segieth J, Whitton PS (1998) N-Methyl-d-aspartate receptors regulate 5-HT release in the raphe nuclei and frontal cortex of freely moving rats: differential role of 5-HT1A autoreceptors. Brain Res 783:173–178. doi:10.1016/S0006-8993(97)01333-4
34. Perkins D (2004) Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 185:18–24. doi:10.1192/bjp.185.1.18
35. Perlis RH, Alpert J, Nierenberg AA, Mischoulon D, Yeung A, Rosenbaum JF, Fava M (2003) Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand 108:432–438. doi:10.1046/j.0001-690X.2003.00168.x
36. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81:559–575. doi:10.1086/519795
37. R Foundation for Statistical Computing (2011) R: A language and environment for statistical computing
38. Reierson GW, Guo S, Mastronardi C, Licinio J, Wong M-L (2011) cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Curr Neuropharmacol 9:715–727. doi:10.2174/157015911798376271
39. Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241. doi:10.1001/archpsyc.56.3.241
40. Ruhé HG, Mason NS, Schene AH (2007) Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331–359. doi:10.1038/sj.mp.4001949
41. Rush A (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report. Am J Psychiatry 163:1905. doi:10.1176/appi.ajp.163.11.1905
42. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB (2003) The 16-Item Quick Inventory Of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583. doi:10.1016/S0006-3223(02)01866-8
43. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, STAR*D Investigators Group (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142. doi:10.1016/S0197-2456(03)00112-0
44. Schulz R, Drayer RA, Rollman BL (2002) Depression as a risk factor for non-suicide mortality in the elderly. Biol Psychiatry 52:205–225
45. Semiz UB, Cetin M, Basoglu C, Ebrinc S, Uzun O, Herken H, Balibey H, Algul A, Ates A (2007) Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31:1330–1336. doi:10.1016/j.pnpbp.2007.06.002
46. Shelton RC, Sanders-Bush E, Manier DH, Lewis DA (2009) Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158:1406–1415. doi:10.1016/j.neuroscience.2008.11.036
47. Shi Y, Yuan Y, Xu Z, Pu M, Wang C, Zhang Y, Liu Z, Wang C, Li L, Zhang Z (2012) Genetic variation in the calcium/calmodulin-dependent protein kinase (CaMK) pathway is associated with antidepressant response in females. J Affect Disord 136:558–566. doi:10.1016/j.jad.2011.10.030
48. Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100:4–22. doi:10.1111/j.1742-7843.2007.00017.x
49. Stewart RJ, Chen B, Dowlatshahi D, MacQueen GM, Young LT (2001) Abnormalities in the cAMP signaling pathway in post-mortem brain tissue from the Stanley Neuropathology Consortium. Brain Res Bull 55:625–629
50. Thome J, Sakai N, Shin K, Steffen C, Zhang YJ, Impey S, Storm D, Duman RS (2000) cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci Off J Soc Neurosci 20:4030–4036
51. Trivedi MH (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40. doi:10.1176/appi.ajp.163.1.28
52. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1–10. doi:10.1016/0014-2999(90)90204-J
53. Usall J, Suarez D, Haro JM (2007) Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res 153:225–231. doi:10.1016/j.psychres.2006.09.016
54. Van der Weide J, Steijns LS, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13:169–172. doi:10.1097/01.fpc.0000054065.98065.a0
55. Wand GS, Levine MA (1991) Hormonal tolerance to ethanol is associated with decreased expression of the GTP-binding protein, Gs alpha, and adenylyl cyclase activity in ethanol-treated LS mice. Alcohol Clin Exp Res 15:705–710